HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $34
HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $27 to $34.
Stocks · News reference
Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Adicet Bio shares are trading lower after the company announced safety and efficacy data from the Phase 1 study evaluating prulacabtagene leucel as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis.
8-K filing — Adicet Bio, Inc. (ACET)
Filed: 2026-09-28 AccNo: 0001720580-26-000060 Size: 15 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits